Remember that volatility creates volatility–time to look to some tax loss selling (like Nektar)

Remember that volatility creates volatility–time to look to some tax loss selling (like Nektar)

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Nektar should be climbing but this fast?

Nektar should be climbing but this fast?

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

Nektar’s new non-addictive opioid NKTR-181 to finally get an FDA advisory vote tomorrow

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness

Adding Nektar call options to my Volatility Portfolio–again

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200